Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on May 31, 2014 12:32pm

292 Views

Post# 22618009

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lack of communications

Great post Sanfran and thanks bengtpress for explaining the value of ph2iii trial.

I think a CVR deal would be great for the reasons you explained, but if the initial buy out was for, say, $1.00/share I would not be happy. I don't know KD but he is a billionnaire and I'm sure he would not want lose this company to receive $15,000,000 up front (unless he wants to reduce his risk profile) and then payments at hurdle points if rvx-208 succeeds. I would hope his influence would push the upfront payout to a much higher level.

If the initial buyout was at $20 then KD stands to make $300,000,000 and future potential benefits. This probably is attractive but if rvx-208 succeeds it will be a multi-billion dollar business each year and he loses out on that aspect unless the deal is structured based on shares of the suitor or an annuity formula.

The potential for rvx-208 seems to be growing in leaps and bounds in terms of what is emerging as multi-faceted health benefits - reduction of major cardiovascular events, plaque regression, diabetis, Alzheimers and then the secondary benefits to other organs. It's potential seems absolutelly huge and it should not be sold short (pardon the pun).

And remember BP needs innovation and compounds that have moved to later stages of development.

Zenith, on it's own, has tremendous potential because it is the chemical factory (or software) to produce many chemicals specific to individuals as well as populations and this is the future of treatments for cancer and many other diseases.

The Friday numbers were great. Who knows what Monday will bring. I've been speculating as follows:

I think there is a very high probability that ph2iii will happen one way or the other.
As each week goes by the time for the announcement is getting close...probably very close now.
Investors that have been sitting on the sidelines are starting to buy in because they could get a real good gain if a CVR is announced or even by the effect of the announcement of the trial.
There is lots of positive activity such as the new offices, the diabetes trail, Alzheimers and other findings.

So hopefully we'll see continued action in positive movement. IMO the potential is huge.

The Stockhouse site is a bit finiky.

Cheers
Toinv

Bullboard Posts

Changing Europe’s dependency on HREE from China